One of Bitcoin’s most prominent investors is making a new monster bet.
Exploring the companies and themes that make up this emerging and exciting new sector
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth
Cybin Corp acquires Adelia Therapeutics in an all-stock transaction valued at CAD$20.2 million.
Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering
Numinus announces a bought deal financing at CAD$0.68 cents.
BIG Financings Powering Future Profits in Psychedelic Stocks
Nearly $400 million dollars has recently flooded into the coffers of psychedelic drug companies. That's enough capital to power a lot of growth.
Oregon wants experts for new psilocybin-assisted therapy board
Oregon’s effort to create a new psilocybin-assisted therapy system has attracted attention from across the country.
Mind Cure Announces Eligibility for DTC Trading
Mind Cure stock is now much more easily accessible for U.S.-based investors.
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
Numinus' Vancouver clinic will be used for collaboration on a clinical trial with MAPS for MDMA-assisted therapy for PTSD.
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
Entheon announces an agreement for the purpose of conducting a Phase 1 clinical trial.
The Psychedelics Revolution: It’s No Longer BAD To Feel GOOD
A Psychedelic Drug Revolution is occurring -- to bring badly needed psychedelic medicines to a world suffering from a Mental Health Crisis.
Entheon Biomedical to Begin Trading on the Frankfurt Exchange
Entheon adds a German listing to its original CSE listing.
MindMed Upsizes Previously Announced Bought Deal Public Offering
MindMed's CAD$25-million bought deal financing becomes a $30 million financing -- the same day.
MindMed Announces 2nd $25 Million Bought Deal Public Offering
MindMed's most recent financing is at nearly double where it priced units just 6 weeks earlier.